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Abstract  
 
The aldo-keto reductase 1C3 isoform (AKR1C3) plays a vital role in the biosynthesis of 
androgens, making this enzyme an attractive target for castration-resistant prostate cancer 
(CRPC) therapy. Although AKR1C3 is a promising drug target, no AKR1C3-targeted agent 
has to date been approved for clinical use. Flufenamic acid, a non-steroidal anti-inflammatory 
drug, is known to potently inhibit AKR1C3 in a non-selective manner as COX off-target 
effects are also observed. To diminish off-target effects, we have applied a scaffold hopping 
strategy replacing the benzoic acid moiety of flufenamic acid with an acidic 
hydroxyazolecarbonylic scaffold. In particular, differently N-substituted hydroxylated 
triazoles were designed to simultaneously interact with both subpockets 1 and 2 in the active 
site of AKR1C3 isoform, larger for AKR1C3 than other AKR1Cs isoforms. Through 
computational design and iterative rounds of synthesis and biological evaluation, novel 
compounds are reported, sharing high selectivity (up to 230-fold) for AKR1C3 over 1C2 
isoform and minimal COX1 and COX2 off-target inhibition. A docking study of compound 
8, the most interesting compound of the series, suggested that its methoxybenzyl substitution 
has the ability to fit inside subpocket 2, being involved in π-π staking interaction with Trp227 
(partial overlapping) and in a T-shape π-π staking with Trp86. This compound was also 
shown to diminish testosterone production in the AKR1C3-expressing 22RV1 prostate cancer 
cell line while synergistic effect was in combination with abiraterone and enzalutamide.  
 
1. Introduction  
 
Prostate cancer (PCa) is the most commonly diagnosed cancer in men and the second leading 
cause of death.[1] Individuals diagnosed with high-risk prostate cancer are typically treated 
with surgery or a combination of radiation and androgen deprivation therapy (ADT). Many 
will inevitably relapse and ultimately develop castration-resistant prostate cancer (CRPC), 
which is responsible for the vast majority of PCa mortalities. Accordingly, there is an unmet 
clinical need to develop new therapies for the treatment of CRPC patients. Although the 
mechanisms of resistance are multi-factorial, the androgen axis still plays a major role in 
being active even after ADT.[2] Beside evidence that androgen receptor (AR) mutations, 
splice variants and increased copy number represent putative mechanisms of resistance to 
therapy,[3-6] the increased expression of enzymes able to facilitate the intratumoral 
2 
conversion of circulating adrenal androgen precursors to the active AR ligands
 
could be 
responsible of the CRPC surviving mechanisms.[7] In CRPC cells the aldo-keto reductase 
1C3 (AKR1C3 or 17β-HSD5) is highly expressed.[5] This enzyme, which catalyzes the 
reduction of carbonyl substrates derived from both endogenous compounds and 
xenobiotics,[8] is a key player in several steps of the complex biochemical pathways leading 
to androgen production of potent AR ligands, as testosterone (T) and 5α-dihydrotesterone  
(DHT).[8]
 
Moreover, AKR1C3 has also been discovered to play roles in resistance to both 
hormone[5] and radiation therapy.[9]
 
Potential clinical use of AKR1C3 inhibitors has been 
demonstrated as indomethacin, a potent but unselective AKR1C3 inhibitor, is able to 
circumvent resistance to the steroidogenic enzyme CYP17A1 abiraterone,[10] and to the AR 
antagonist enzalutamide.[11] Although a few recent studies indicate controversial 
observations about the in vivo effectiveness of AKR1C3-based therapies,[12-14] other 
studies strongly indicate AKR1C3 as a therapeutic target in PCa.[3, 15] Although several 
lead compounds have emerged,[16-19] the pharmacopeia still lacks an AKR1C3-targeted 
drug with clinical potential.  
 
 
 
Figure 1. Chemical structures of flufenamic acid, indomethacin and AKR1C3 inhibitors 
recently deep evaluated. 
In order to understand several key unanswered questions related to the in vivo application of 
AKR1C3 inhibitors, it is desirable to develop more potent, selective and drug-like AKR1C3 
inhibitors. Amongst NSAIDs, flufenamic acid (FLU, Figure 1) potently inhibits AKR1C3 
although it is known to suffer from COX off-target effects.[20, 21] Recently, we successfully 
applied a scaffold hopping strategy based on the replacement of quinolinecarboxylate moiety 
of brequinar with a hydroxyazolecarboxamidic scaffold for the design of new potent human 
dihydroorotate dehydrogenase (hDHODH) inhibitors.[22] In the present study, we applied a 
similar scaffold hopping strategy to the FLU benzoic acid moiety (Figure 2). Specifically, 
three hydroxyazoles (hydroxyfurazan, hydroxythiadiazole and a series of N-substituted 
hydroxyl-1,2,3-triazoles) were used to design compounds 1 – 8 (Figure 2). Due to their acidic 
properties their hydroxylazole scaffolds are widely deprotonated at physiological pH and are 
valid isosters of the carboxylic acid function as recently demonstrated by us.[23-25] In 
contrast to the hydroxyfurazan and hydroxythiadiazole scaffolds, the regiosubstitution of the 
nitrogen of the hydroxyltriazole ring allows the possibility to make a structural refinement, 
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which enables an opportunity to improve on binding pocket affinity. Accordingly, the 
substituents present on the triazole ring (Figure 2) were selected by their possibility of 
establishing interactions with sub-pocket 2 (SP2) of the AKR1C3 binding site[26] in an 
attempt to enhance target selectivity. 
 
Figure 2. AKR1C3 inhibitors based on hydroxyazole scaffolds. 
 
We here report on the design, synthesis and biological explorations of eight candidate 
structures (Figure 2), which supports the findings of AKR1C3-selective compounds with no 
off-target COX effect. Furthermore, the binding modes of the most representative molecules 
were suggested by computational modelling. 
 
2. Result and discussion 
 
2.1 Chemistry. 
 
The methodology used for the synthesis of the target compounds is described in scheme 1. 
The first part of the work consisted in acquiring the protected benzyloxyazolecarboxylic 
acids (13, 16a-f, Scheme 1a and 1b) to couple to 3-trifluoromethylaniline (Scheme 1c). 4-
Benzyloxy-1,2,5-oxadiazole-3-carboxylic acid 13 was prepared from 9 [25] by hydrolysis 
under basic condition to yield the corresponding acid 10. This latter was decarboxylated and 
dehydrated to the nitrile 11 then transformed into the methyl ester 12 by a Pinner reaction. 
Compound 13 was finally obtained by base-catalyzed hydrolysis of 12 (Scheme 1a). To 
obtain regio-substituted hydroxytriazole carboxylic acids 16 a-f, we recently presented a 
methodology starting from 14 as a common starting material.[23] This building block 
presents an alkylation pattern directed toward positions N(b) and N(c) of the triazole ring, 
leading to a mixture of two isomeric products. The isomeric mixtures were 
chromatographically resolved and each isomer structurally assigned on the basis of the 
heteronuclear 2D-NMR (HSQC and HMBC) and 
13
C-NMR spectra.[27] The hydrolysis of 
the obtained esters 15 a-f afforded the carboxylic acids of general structure 16 (Scheme 1b). 
Finally, carboxylic acids 13 and 16a-f were converted into the corresponding acyl chlorides 
and allowed to react with 3-trifluoromethylaniline to generate the amides 18 and 19a-f; these 
latter compounds were deprotected through catalytic hydrogenation to give the desired target 
compounds 1, 3 – 8 (Scheme 1c). Compound 2 was directly obtained from coupling of 
unprotected 4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid 17[28] with 3-
trifluoromethylaniline. In this case, the protection of the hydroxyl group of 17 was avoided, 
which poses challenges to the removal of benzylic group already observed for other 4-
benzyloxy-1,2,5-thiadiazole-3-carboxamides[22]. The reaction of unprotected acid 17 with 3-
4 
trifluoromethylaniline resulted a low yield passage, but allowed an easy purification of 
desired product 2. 
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Scheme 1. (a) 1) NaOH, EtOH, rt; 2) 2M HCl; (b) Ac2O, 70°C; (c) NaH, dry MeOH, (d) 2M 
H2SO4; (e) RX, K2CO3, CH3CN, r.t.; (f) ClCOCOCl, dry DMF, dry THF, 0°C; (g) 3-
trifluoromethylaniline, dry pyridine, dry THF, r.t.; (h) H2, Pd/C, THF, r.t.. 
 
2.2 AKR1C3 inhibition assays. 
 
The activity of the compounds 1 - 8 and FLU as AKR1C3 inhibitors was initially tested by 
incubating a bacterial suspension containing recombinant AKR1C3 with radiolabeled [
14
C]-
androstenedione in the presence of increasing inhibitor concentrations (Table 1). In 
comparison with FLU (IC50 8.63 µM), the hydroxyfurazan 1, the hydroxythiadiazole 2 and 
the N(b) methyl triazole 3 were found to be almost inactive while the N(c) methyl triazole 4 
(IC50 = 32.79 µM) demonstrated weak inhibitory activity. Furthermore, the two 
cyclopropylmethyl triazoles 5 and 6, the N(c) isomer resulted in more active compound than 
the N(b) analogue. As the binding site seems to better tolerate the N(c) substitution, we 
designed two more N(c) analogues with substituents of increasing size (7 and 8). Indeed N(c) 
5 
cyclopropylmethyl triazole 6 was shown to be more active than N(c) methyl triazole 4, 
indicating the preference for lipophilic groups in that position. This hypothesis was 
confirmed as the benzyl 7 and 4-methoxylbenzyl 8 analogues displayed activity (IC50s of 
10.19 µM and 3.56 µM, respectively) comparable with FLU. Notably, with compound 8 was 
shown to be more potent than FLU under the conditions investigated.  
 
Table 1. Inhibitory effect on AKR1C3 and AKR1C2 recombinant enzymes. 
 Bacterial suspension
 
Purified enzyme
 
Compound 
AKR1C3 
IC50 ± SE  
(µM)
 a
 
AKR1C3 
IC50 ± SE  
(µM)
 b
 
AKR1C2 
IC50 ± SE 
(µM)
 b
 
Ratio 
IC50 value 
(1C2:1C3) 
FLU 8.63 ± 1.70 0.44 ± 0.023 0.53 ± 0.032 1.2 
1  >50 
(35.37% ± 3.37)
c
 
n.d. n.d. n.d. 
2 ≥ 50 
(47.22% ± 3.16)
c 
n.d. n.d. n.d. 
3 >50
 
(18.47% ± 3.71)
 c
 
n.d. n.d. n.d. 
4 
32.79±1.10 
n.d. n.d. n.d. 
5 >50
 
(5.35% ± 1.44)
 c
 
n.d. n.d. n.d. 
6 13.22 ± 0.81 1.60 ± 0.22 70.63 ± 6.32 44 
 
7 
10.19±1.47 0.48 ± 0.025 62.94 ± 5.13 131 
8 3.56±0.08 0.31 ± 0.005 73.23 ± 8.67 236 
 
a) experiments performed with [
14
C]androstenedione as substrate; b) experiments performed with S-tetralol as 
substrate; c) % of inhibition ± SE at 50 µM. n.d: not determined. 
 
The three most active compounds assayed in the bacterial suspension assay (6 - 8) were also 
assayed with AKR1C3 purified enzyme (Table 1) by following the oxidation of S-tetralol in 
the presence of NADP
+
. The inhibition pattern observed was similar to that observed with the 
bacterial suspension. Notably, compounds 7 and 8 were equipotent (IC50 0.48 µM and 0.31 
µM, respectively) with FLU (IC50 0.44 µM). 
 
2.3. AKR1Cs selectivity and COX inhibition. 
 
In PCa therapy, selective targeting of AKR1C3 over 1C2 is considered critical [29]: 
AKR1C2 share > 86% sequence identity with AKR1C3, and it is also involved in 
dihydrotestosterone inactivation, so its inhibition would be undesirable. Hence, the most 
active compounds 6 - 8 and FLU were assayed for their inhibitory properties using purified 
AKR1C2 incubated with S-tetralol (Table 1). Whereas the AKR1C2/C3 inhibition ratio of 
FLU was found to be 1.2, triazole analogues 7 and 8 were found to be 131 and 236-fold more 
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selective toward AKR1C3 inhibition. Next, the compounds 6 - 8 were assayed for their 
inhibitor effect on COX-1 and COX-2 off-target. Their activity, compared with different 
standards using ovine COX-1 (oCOX-1) and human COX-2 (hCOX-2) is reported in Table 2.  
 
Table 2. COX-1 and COX-2 inhibitory activities of compounds 6, 7 and 8, compared with 
flufenamic acid, indomethacin, celecoxib and rofecoxib. 
Compound 
oCOX1  
IC50 ± SE (µM) 
hCOX2  
IC50 ± SE (µM) 
Ratio 
IC50 value 
(COX1:AKR1C3) 
Ratio 
IC50 value 
(COX2:AKR1C3) 
FLU 14 ± 1 
> 100 
(18% ± 2)
a
 
32 > 227 
6 
> 100 
(17% ± 1)
a 
> 100 
(9.6% ± 5.2)
a
 
> 63 > 63 
7 
> 100 
(15% ± 4)
 a
 
> 100 
(7.5% ± 7.5)
 a
 
> 208 > 208 
8 
>100
 
(0)
 a
 
>100
 
(12% ± 4)
 a
 
> 322 > 322 
Indomethacin 0.10 ± 0.01 0.61 ± 0.09 n.d. n.d. 
Celecoxib 14 ± 12 0.54 ± 0.12 n.d. n.d. 
Rofecoxib 
˃100 
(25 ± 14)
a
 
3.0 ± 1.0 n.d. n.d. 
 a) % of inhibition ± SE at 100 µM. n.d: not determined. 
 
Notably, compounds 6 - 8 did not display significant inhibitory activity on any of the two 
COX isoforms at the highest concentration tested (100 µM). In contrast, FLU was shown to 
be effective in inhibiting COX-1 but not COX-2. Because contradictory data are reported in 
the literature for FLU and COX inhibition,[30] we validated our assay with indomethacin 
(time-dependent non-selective inhibitor[30]), celecoxib and rofecoxib (non-time-dependent 
for COX-1, time-dependent and selective for COX-2).[31, 32] Pleasingly, the COX 1/2 data 
obtained was consistent with inhibitory potencies reported in literature.[33, 34]  
 
2.4 Antiproliferative activity and testosterone suppression. 
 
We evaluated compounds 7, 8 and FLU in AKR1C3-expressing 22RV1 cells, which have 
been shown to possess resistance to abiraterone and enzalutamide.[10-12] The presence of 
AKR1C3 was confirmed using western blot (Figure 3A) before assessing the antiproliferative 
activity of three compounds using the SRB assay. Although compound 7 appeared to be a 
less potent inhibitor of AKR1C3 than both 8 and FLU, it was observed to be slightly more 
antiproliferative (Figure 3B). As AKR1C3 plays a key role in the production of testosterone 
in the androgen biosynthetic pathway, therapeutic intervention of this pathway is vital to 
effective treatment outcome. Given that 8 had a higher AKR1C3:AKR1C2 selectivity ratio 
than 7, we decided to evaluate the former for its ability to interfere with testosterone 
formation. In the presence of androstenedione (28 nM), testosterone production was 
increased > 200-fold in 22RV1 cells. When cells were treated with 8, a significant dose-
dependent impact on testosterone levels was observed (Figure 3C). In particular a 30% 
decrease testosterone production of the was observed when the cells were treated with 5µM 
7 
solution of 8. This decrease reach the 50% with a 10 µM solution. of   quindi la riduzione 
della formazione di testosterone osservata su enzima isolato si verifica anche su cellula. 
 
 
 
Figure 3. Antiproliferative activity and testosterone production. Confirmation of AKR1C3 
expression in 22RV1 cells by western blot (A) and antiproliferative activity of compounds 7, 
8 and FLU using the SRB assay (B). Evaluation of the inhibitory effect of compound 8 in 
androstenedione treated 22RV1 cells (C). 
 
In order to evaluate a possible synergistic effect of our compounds with abiraterone and 
enzalutamide, experiments of co-treatment were performed. 22RV1 cells were treated with 
60 µM compound 8 with or without 10 µM abiraterone for 72 h. The same experiment was 
carried out by treating cells with or without 20 µM enzalutamide. As shown in Figure 4, 
abiraterone, enzalutamide and compound 8 had, each, limited effects on cell growth. When 
compound 8 was added together with either abiraterone or enzalutamide, the cell viability 
was reduced to 45% or 50%, respectively, suggesting a synergistic effect was achieved. 
 
 
Figure 4. Effect of the co-treatment with compound 8 and abiraterone or enzalutamide on 
22RV1 cells proliferation by SRB. Cells were treated with 60 µM compound 8 with or 
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without 10 µM abiraterone (or 20 µM enzalutamide) for 72 h. Cell growth is expressed as % 
T/C (mean OD of treated cells/mean OD of control cells X 100).  
 
2.5 Molecular modeling 
 
To elucidate the observed activity of hydroxytriazole-based compounds, we performed a 
molecular docking study starting from the crystal protein complexed with FLU (PDB code: 
1S2C) and using the Schrödinger QM-Polarized Ligand Docking protocol.[35] A stereo view 
showing FLU (orange) and compound 8 (grey) docked in the AKR1C3 binding site is 
presented in Figure 5. At first, self-docking procedure was successfully applied on FLU 
reproducing the crystallographic coordinate of FLU inside the binding site (Figure S1). The 
binding mode of FLU shows the carboxylate moiety interact with the so-called oxanion hole 
(OS) involving hydrogen bonds with Tyr55 and His117 and a water molecule with the 
NADP
+
 co-factor. The trifluoromethylphenyl moiety is directed toward the sub-pocket 1 
(SP1), composed of Ser118, Asn167, Phe306, Phe311, Tyr216, Met120 and Tyr319, where it 
is involved in lipophilic interactions. The binding mode retrieved from docking studied on 
compound 8 revealed a high superimposition to FLU (Figure 5). In particular, the hydroxyl 
group present in the triazole ring was shown anchored in the OS, thereby mimicking the 
carboxylic group of FLU. The amide link present in compound 8 compared to the amine in 
FLU, extends the occupied space of trifluoromethylphenyl moiety inside SP1. This fact could 
explain the AKR1C3 selectivity of 8, as the AKR1C2 isoform is characterized by a smaller 
SP1.[29] Interestingly, the 4-methoxy-benzyl substituent of 8 has the ability to fit inside SP2, 
a small pocket part of the SC left unoccupied by FLU. Docking results suggest for the N(c) 4-
methoxy-benzyl substituent the presence of a π-π staking interaction with Trp227 (partial 
overlapping) and T-shape π-π staking with Trp86. 
 
 
Figure 5. Stereo view of FLU (orange) and compound 8 (grey) docked in the AKR1C3 
binding site. NADP
+
 is coloured in green. 
 
3. Conclusions 
 
This study has focused on a new generation of AKR1C3 inhibitors designed by utilizing a 
scaffold hopping approach to replace the benzoic acid moiety of FLU with hydroxylated 
azoles. The best compound of the series, the 4-methoxybenzyl substituted analogue 8, was 
found to selectively inhibit AKR1C3 activity without any significant AKR1C2 and COX1/2 
off-target effects. Compound 8 was also able to inhibit the testosterone production and cell 
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proliferation in AKR1C3-expressing 22RV1 CRPC cells. In addition, the inhibition of 
AKR1C3 activity by compound 8 partly resensitized 22RV1 cells to enzalutamide and 
abiraterone treatment. Taken together, the novel chemical scaffolds provides a promising 
starting point for the design of more potent AKR1C3 inhibitors with clinical potential. 
 
4. Experimental section 
 
4.1 Chemistry  
 
4.1.1 General methods. All chemical reagents were obtained from commercial sources 
(Sigma Aldrich, Alfa Aesar) and used without further purification. Culture media were 
obtained from Sigma‑Aldrich. Restriction enzymes, DNA polymerase and T4 DNA ligase 
were obtained from Promega. [4-
14
C]-androst-4-ene-3,17-dione (10 µCi/370 KBq, 53.6 
mCi/mmol) was obtained from Perkin-Elmer. Analytical grade solvents (acetonitrile, 
diisopropyl ether, diethyl ether, dichloromethane [DCM], dimethylformamide [DMF], 
ethanol 99.8 % v/v, ethyl acetate, methanol [MeOH], petroleum ether b.p. 40 - 60°C 
[petroleum ether]) were used without further purification. When needed, solvents were dried 
on 4 Å molecular sieves. Tetrahydrofuran (THF) was distilled immediately prior to use from 
Na and benzophenone under N2. Thin layer chromatography (TLC) on silica gel was carried 
out on 5 x 20 cm plates with 0.25 mm layer thickness to monitor the process of reactions. 
Anhydrous MgSO4 was used as a drying agent for the organic phases. Purification of 
compounds was achieved with flash column chromatography on silica gel (Merck Kieselgel 
60, 230-400 mesh ASTM) using the eluents indicated or by CombiFlash Rf 200 (Teledyne 
Isco) with 5–200 mL/min, 200 psi (with automatic injection valve) using RediSep Rf Silica 
columns (Teledyne Isco) with the eluents indicated. Purity was checked using two analytical 
methods. HPLC analyses were performed on an UHPLC chromatographic system (Perkin 
Elmer, Flexar). The analytical column was an UHPLC Acquity CSH Fluoro-Phenyl (2.1x100 
mm, 1.7 µm particle size) (Waters). Compounds were dissolved in acetonitrile and injected 
through a 20 µl loop. The mobile phase consisted of acetonitrile / water with 0.1 % 
trifluoroacetic acid (ratio between 60 / 40 and 40 / 60, depending on the compound’s 
retention factor). UHPLC analysis were run at flow rates of 0.5 mL/min, and the column 
effluent was monitored at 215 and 254 nm, referenced against a 360 nm wavelength. Purity 
of the synthetic intermediates varied between 90 % and 99 % purity. The biological 
experiments were employed on compounds with a purity of at least 95%. Melting points 
(m.p.) were measured on a capillary apparatus (Büchi 540) by placing the sample at a 
temperature 10° C below the m.p. and applying a heating rate of 1° C min
-1
. All compounds 
were routinely checked by 
1
H- and 
13
C-NMR and mass spectrometry. 
1
H- and 
13
C-NMR 
spectra were performed on a Bruker Avance 300 instrument. For coupling patterns, the 
following abbreviations are used: br = broad, s = singlet, d = doublet, dd = doublet of 
doublets, t = triplet, q = quartet, m = multiplet. Chemical shifts (δ) are given in parts per 
million (ppm). MS spectra were performed on Finnigan-Mat TSQ-700 (70 eV, direct inlet for 
chemical ionization [CI]) or Waters Micromass ZQ equipped with ESCi source for 
electrospray ionization mass spectra. Compounds 9,[25] 15a, 15b, 15e,[23] 15c, 15d, 16a-
d,[22] 17[28]were prepared following already described procedures. 
 
4.1.2. 2-[4-(Benzyloxy)-1,2,5-oxadiazol-3-yl](hydroxyimino)acetic acid (10). 5M NaOH (8 
mL) was added to a solution of 9 (2.21 g; 7.60 mmol) in ethanol (40 ml). The reaction 
mixture was stirred at room temperature for 24 h, then concentrated under reduced pressure. 
The crude material was dissolved in water (15 mL) and acidified with HCl until precipitation 
of the desired product occurred. The white obtained solid was a mixture of the two 
geometrical isomers in variable ratio. Yield 76 %. 
1
H-NMR (300 MHz, most abundant 
isomer, DMSO-d6): δ 5.32 (s, 2H), 7.29 - 7.32 (m, 5H), 13.59 (s, 1H), 13.80 (br s, 1H). 
13
C-
10 
NMR (DMSO-d6): δ 74.0, 128.7, 128.8, 128.9, 134.9, 136.5, 139.6, 162.6, 163.3. MS (CI) 
263 [M + H]
+
. 
4.1.3. 4-(Benzyloxy)-1,2,5-oxadiazole-3-carbonitrile (11). A solution of 10 (1.30 g; 4.94 
mmol) in acetic anhydride (13 ml) was stirred at 70 °C for 2 h. The reaction mixture was 
cooled to r.t. and concentrated under reduced pressure to half volume, then poured into iced 
water (50 ml). The resulting mixture was stirred at room temperature for 30 min then 
extracted twice with diethyl ether. The organic collected layers were washed with saturated 
NaHCO3, brine, dried with Na2SO4 and concentrated under reduced pressure. The oily crude 
was purified by flash chromatography using DCM as eluent to afford the title compound as a 
white solid (m.p. 44-45 °C). Yield 92 %. 
1
H-NMR (300 MHz, CDCl3): δ 5.35 (s, 2H), 7.34 - 
7.42 (m, 5H). 
13
C-NMR (CDCl3): δ 75.7, 106.3, 125.9, 129.0, 129.1, 129.8, 133.2, 164.6. MS 
(CI) 202 [M + H]
+
. 
4.1.4. Methyl 4-(benzyloxy)-1,2,5-oxadiazole-3-carboxylate (12). Sodium hydride 60 % 
dispersion in mineral oil (398 mg) was added to a solution of 11 (1.00 g; 4.98 mmol) in dry 
methanol (10 mL). The reaction mixture was stirred under nitrogen atmosphere at 0 
o
C for 15 
min, then allowed to reach room temperature and further stirred for 60 min. 2M H2SO4 (10 
ml) was slowly added cooling the reaction mixture at 0°C. The resulting suspension was 
extracted with DCM. The organic layers were collected, dried and concentrated under 
reduced pressure. The crude material was purified by flash chromatography using petroleum 
ether / DCM 6:4 v/v as eluent, to afford the title compound as white solid (m.p. 45 °C). Yield 
98 %. 
1
H-NMR (300 MHz, CDCl3): δ 3.91 (s, 3H), 5.35 (s, 2H), 7.29-7.43 (m, 5H). 
13
C-
NMR (CDCl3): δ 53.1, 74.4, 128.3, 128.6, 128.9, 134.0, 139.2, 157.4, 163.7. MS (CI) 235 [M 
+ H]
+
. 
4.1.5. Ethyl 4-(benzyloxy)-1-(4-methoxybenzyl)-1H-1,2,3-triazole-5-carboxylate (15f). 
Cs2CO3 (8.91 mmol) and 1-(chloromethyl)-4-methoxybenzene (1.23 g, 7.94 mmol) were 
added to a solution of 14 (1.10 g, 4.45 mmol) in CH3CN (25 ml). The resulting mixture was 
stirred at room temperature for 16 hours. When the reaction was complete, the mixture was 
concentrated under reduced pressure, the crude product was extracted with EtOAc (50 mL) 
and the resulting suspension washed with 1M HCl (30 mL), 1M NaOH (30 mL) and brine. 
The organic phase was dried and concentrated under reduced pressure to afford a colorless 
oil. The latter showed two spots on TLC (eluent: petroleum ether /EtOAc 90/10 v/v) relative 
to the N(b) and N(c) substituted triazole isomers. The two isomers were separated using flash 
chromatography (eluent: petroleum ether / EtOAc 95/5 v/v). First eluted isomer, white solid 
(m.p. 76.5 - 78.7 °C). Yield 36 %. 
1
H-NMR (300 MHz, DMSO-d6): δ 1.24 (3H, t, J = 7.1 
Hz), 3.72 (3H, s), 4.27 (2H, q, J = 7.1 Hz), 5.45 (2H, s), 5.73 (2H, s), 6.90 (2H, d, J = 8.5 
Hz), 7.18 (2H, d, J = 8.7 Hz), 7.29 - 7.50 (5H, m); 
13
C-NMR (DMSO-d6): δ 13.9, 53.5, 55.1, 
61.1, 71.1,  110.4, 114.1, 127.5, 127.6, 128.1, 128.4, 129.1, 136.4, 157.7, 159.1, 160.6. MS 
(ESI) 368 [M + H]
+
. The second eluted isomer ethyl 5-(benzyloxy)-2-(4-methoxybenzyl)-2H-
1,2,3-triazole-4-carboxylate was also isolated as a white solid and characterized. M.p. 80.7 – 
81.7 °C, from ethanol. Yield 60 %. 
1
H-NMR (300 MHz, DMSO-d6): δ 1.26 (t, J = 7.1 Hz, 
3H), 3.74 (s, 3H), 4.25 (q, J = 7.1 Hz, 2H), 5.30 (s, 2H), 5.48 (s, 2H), 6.92 (d, J = 8.6 Hz, 
2H), 7.27 (d, J = 8.6 Hz, 2H), 7.31 - 7.49 (m, 5H). 
13
C-NMR (DMSO-d6): δ 14.0, 55.0, 58.3, 
60.3, 71.7, 113.9, 123.0, 126.7, 127.8, 128.1, 128.3, 129.5, 135.8, 159.1, 159.4, 160.1. MS 
(ESI) 368 [M + H]
+
. 
4.1.6. General procedure for compounds 16e, 16f and 13. 
6M NaOH (0.57 mL, 3.45 mmol) was added to a solution of the appropriate ester (1.15 
mmol) in ethanol (25 mL) and the reaction mixture was stirred at room temperature until 
disappearance of starting material. The resulting solution was neutralized with 2M HCl, then 
concentrated under reduced pressure. 2M HCl was added until pH 1-2, observing 
11 
precipitation of a white solid. The solid was isolated by filtration to give the appropriate 
carboxylic acid. 
4.1.6.1 4-(Benzyloxy)-1,2,5-oxadiazole-3-carboxylic acid (13). White solid (m.p. 106-107 °C 
from hexane/diisopropyl ether). 
1
H-NMR (300 MHz, CDCl3): δ 5.45 (s, 2H), 7.30 - 7.50 (m, 
5H), 10.91 (br s, 1H). 
13
C-NMR (CDCl3): δ 74.8, 128.7, 128.8, 129.1, 134.0, 139.1, 161.6, 
163.9. MS (CI) 220 [M + H]
+
. 
4.1.6.2 1-Benzyl-4-(benzyloxy)-1H-1,2,3-triazole-5-carboxylic acid (16e). White solid (m.p. 
165.7 - 166.8°C). Yield 90 %.
 1
H- NMR (300 MHz, DMSO-d6): δ 5.44 (s, 2H), 5.82 (s, 2H), 
7.14‒7.52 (m, 10H), 13.66 ppm (br, 1H). 13C-NMR (DMSO-d6): δ 53.7, 71.1, 111.2, 127.4, 
128.0, 128.1, 128.4, 128.7, 128.7, 135.9, 136.4, 159.1, 160,4. MS (ESI) 310 [M + H]
+
. 
4.1.6.3 4-(Benzyloxy)-1-(4-methoxybenzyl)-1H-1,2,3-triazole-5-carboxylic acid (16f). White 
solid (m.p. 179.1 - 180.5°C). Yield 84 %. 
1
H-NMR (300 MHz, DMSO-d6): δ 3.72 (s, 3H), 
5.43 (s, 2H), 5.73 (s, 2H), 6.90 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 7.29 - 7.51 (m, 5 
H), 13.62 (br, 1H). 
13
C-NMR (DMSO-d6): δ 53.2, 55.1, 71.0, 111.0, 114.0, 127.7, 128.0, 
128.1, 128.4, 129.1, 136.4, 159.1, 159.2, 160.5. MS (ESI) 340 [M + H]
+
. 
4.1.7. General procedure for synthesis of amides 18 - 19a-f: 
Dry DMF (26 μL) and 2M oxalyl chloride in DCM (3.06 mmol, 1.53 mL) were added to a 
cooled (0°C) solution of the appropriate carboxylic acid (13, 16 a - f, 0.901 mmol) in dry 
THF (15 mL). The reaction was stirred for 3 hours at room temperature under nitrogen 
atmosphere. The solvent was evaporated under reduced pressure and the residue was 
dissolved in dry THF (this process was repeated for three times). The resulting acyl chloride 
was dissolved in dry THF (10 mL) and used without any further purification in the next step. 
Dry pyridine (219 μL, 2.70 mmol) and 3-trifluoromethylaniline (113 μL, 0.901 mmol) were 
added to the described solution. The reaction mixture was stirred for 12 hours at room 
temperature under nitrogen atmosphere. 0.5 M HCl was added to the resulting mixture, which 
was concentrated under reduced pressure. The resulting suspension was acidified with 0.5 M 
HCl to pH 2 and extracted with ethyl acetate (3 × 20 mL). The organic phases were collected, 
washed with brine, dried with Na2SO4, and the solvent was evaporated. The crude product 
was purified using flash chromatography (gradient of petroleum ether /ethyl acetate from 
90/10 v/v to 70/30 v/v) to obtain the corresponding amide. 
4.1.7.1. 4-(Benzyloxy)-N-(3-(trifluoromethyl)phenyl)-1,2,5-oxadiazole-3-carboxamide (18). 
Flash chromatography eluent: petroleum ether / ethyl acetate 9:1 v/v. White solid (m.p. 110.1 
– 111.1 °C), yield 74 %. 1H-NMR (300 MHz, CDCl3):  5.48 (s, 2H), 7.39-7.52 (7H, m), 
7.80 (d, J = 7.6 Hz, 1H), 7.91 (s, 1H), 8.58 (br s, 1H). 
13
C-NMR (75 MHz CDCl3):  75.2, 
116.9 (q, J = 3.8 Hz), 122.0 (q, J = 3.7 Hz), 123.1 (q, J = 0.8 Hz), 123.6 (q, J = 272.6 Hz), 
128.7, 128.9, 129.3, 129.9, 131.70 (q, J = 32.1 Hz), 133.9, 137.0, 140.9, 153.8, 163.3. MS 
(CI) 364 [M + H]
+
. 
4.1.7.2. 5-(Benzyloxy)-2-methyl-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-triazole-4-
carboxamide (19a). White solid (m.p. 110.2‒112.3 °C). Yield 76 %. 1H NMR (300 MHz, 
DMSO-d6): δ 4.15 (s, 3H), 5.34 (s, 2H), 7.32‒7.62 (m, 7H), 8.01 (d, J = 8.2 Hz, 1H), 8.26 (s, 
1H), 10.48 (s, 1H). 
13
C NMR (DMSO-d6): δ 42.4, 72.0, 116.2 (q, J = 4.1 Hz), 119.9 (q, J = 
4.1 Hz), 123.6 (q, J = 1.2 Hz), 124.1 (q, J = 272.3 Hz), 125.5, 128.0, 128.2, 128.4, 129.3 (q, J 
= 31.4 Hz), 129.8, 136.0, 139.4, 158.1, 159.4. MS (ESI) 377 [M + H]
+
. 
4.1.7.3. 4-(Benzyloxy)-1-methyl-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-
carboxamide (19b). White solid (m.p. 136.4 – 139.4°C). Yield 58 %. 1H NMR (300 MHz, 
DMSO-d6): δ 4.20 (s, 3H), 5.52 (s, 2H), 7.31‒7.44 (m, 3H), 7.46‒7.66 (m, 4H), 7.85 (d, J = 
12 
8.2 Hz, 1H), 8.08 (s, 1H), 9.90 (s, 1H). 
13
C NMR (DMSO-d6): δ 37.9, 71.8, 114.2, 116.1 (q, J 
=4.1 Hz), 120.6 (q, J = 3.8 Hz), 123.6 (q, J = 1.3 Hz), 123.9 (q, J = 272.3 Hz), 127.9, 128.2, 
128.3, 129.5 (q, J = 31.8 Hz), 130.1, 136.2, 138.6, 155.9, 157.8. MS (ESI) 377 [M + H]
+
. 
4.1.7.4. 5-(Benzyloxy)-2-(cyclopropylmethyl)-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-
triazole-4-carboxamide (19c). White solid (m.p. 79.0 - 80.7 °C). Yield 75 %. 
1
H NMR (300 
MHz, DMSO-d6): δ 0.41‒0.49 (m, 2H), 0.54‒0.62 (m, 2H), 1.29‒1.42 (m, 1H), 4.25 (d, J = 
7.2 Hz, 2H), 5.35 (s, 2H), 7.32 ‒ 7.62 (m, 7H), 8.01 (d, J = 8.2 Hz, 1H), 8.24 (s, 1H), 10.36 
(s, 1H). 
13
C NMR (DMSO-d6): δ 3.6, 10.7, 59.5, 72.0, 116.2 (q, J = 4.3 Hz), 119.9 (q, J = 4.1 
Hz), 123.7 (q, J = 0.7 Hz), 124.1 (q, J = 272.4 Hz), 125.6, 128.2, 128.2, 128.4, 129.3 (q, J = 
31.3 Hz), 129.8, 136.0, 139.4, 158.1, 159.2. MS (ESI) 417 [M + H]
+
. 
4.1.7.5. 4-(Benzyloxy)-1-(cyclopropylmethyl)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-
triazole-5-carboxamide (19d). White solid (m.p. 114.1‒116.0 °C). Yield 63 %. 1H NMR (300 
MHz, DMSO-d6): δ 0.37 - 0.45 (m, 2H), 0.48 - 0.57 (m, 2H), 1.27 - 1.44 (m, 1H), 4.47 (d, J = 
7.3 Hz, 2H), 5.52 (s, 2H), 7.31 - 7.67 (m, 7H), 7.85 (d, J = 8.2 Hz, 1H), 8.08 (s, 1H), 10.06 (s, 
1H). 
13
C NMR (DMSO-d6): δ 3.7, 11.4, 54.9, 71.9, 113.5, 116.1 (q, J = 4.1 Hz), 120.7 (q, J = 
4.3 Hz), 123.6 (q, J = 1.2 Hz), 124.0 (q, J = 272.1 Hz), 128.1, 128.3, 128.4, 129.6 (q, J = 31.5 
Hz), 130.3, 136.3, 138.7, 156.1, 158.0. MS (ESI) 417 [M + H]
+
. 
4.1.7.6. 1-Benzyl-4-(benzyloxy)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-
carboxamide (19e). White solid (m.p. 152.2 - 154.2 °C). Yield 51 %. 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.51 (s, 2H), 5.84 (s, 2H), 7.20 - 7.65 (m, 12H), 7.81 (d, J = 8.1 Hz, 1H), 8.00 
(s, 1H), 10.00 (s, 1H). 
13
C NMR (DMSO-d6): δ 53.4, 72.0, 113. 7, 116.1 (q, J = 3.8 Hz), 
120.8 (q, J = 4.3 Hz), 123.6 (q, J = 0.7 Hz), 124.0 (q, J =, 272.3 Hz), 127.7, 128.1, 128.2, 
128.4, 128.5, 128.8, 129.6 (q, J = 31.7 Hz), 130.3, 135.7, 136.2, 138.6, 155.9, 158.2. MS 
(ESI) 453 [M + H]
+
. 
4.1.7.7 4-(Benzyloxy)-1-(4-methoxybenzyl)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-
5-carboxamide (19f). White solid (m.p. 138.9 – 140.3 °C). Yield 65 %. 1H NMR (300 MHz, 
DMSO-d6): δ 3.70 (s, 3H), 5.49 (s, 2H), 5.75 (s, 2H), 6.89 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 
7.9 Hz, 2H), 7.30‒7.67 (m, 7H), 7.82 (d, J = 8.0 Hz, 1H), 8.01 (s, 1H), 10.00 ppm (s, 1H). 
13
C NMR (DMSO-d6): 52.9, 55.1, 71.9, 113.5, 114.1, 116.1 (q, J = 3.0 Hz), 120.7 (q, J = 3.9 
Hz), 123.6 (q, J = 0.5 Hz), 124.0 (q, J = 272.3 Hz) 127.5, 128.1, 128.3, 128.4, 129.5, 129.6 
(q, J = 31.8 Hz), 130.3, 136.2, 138.6, 155.9, 158.2, 159.2 ppm. MS (ESI) 483 [M + H]
+
. 
4.1.8. General hydrogenation procedure to obtain target compounds 1, 3 - 8. 
The appropriate protected hydroxyazole (18, 19a-f, 0.400 mmol) dissolved in dry THF (20 
mL) was hydrogenated in presence of Pd/C (45 mg) for 1 hour at atmospheric pressure. The 
reaction mixture was filtered off through a short layer of celite and the solvent was 
evaporated under reduced pressure yielding the desired compound.  
4.1.8.1. 4-Hydroxy-N-(3-(trifluoromethyl)phenyl)-1,2,5-oxadiazole-3-carboxamide (1). White 
solid (m.p. 165.3 – 167.5 °C, from diisopropyl ether/hexane). Yield 62 %. 1H-NMR (300 
MHz, (CD3)2CO):  7.56 (d, J = 7.8 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 8.08 (d, J = 8.1 Hz, 
1H), 8.30 (s, 1H), 10.24 (br s, 1H). 
13
C-NMR (75 MHz (CD3)2CO):  117.8 (q, J = 3.9 Hz), 
122.3 (q, J = 3.8 Hz), 124.7, 124.9 (q, J = 272.1 Hz), 131.0, 131.5 (q, J= 32.1 Hz), 139.2, 
142.2, 156.7, 163.5. MS (CI) 274 (M+1). ESI-HRMS (m/z) [M - H]
-
 calcd. for C10H5F3N3O3 
272.0278, obsd. 272.0274. 
4.1.8.2. 5-Hydroxy-2-methyl-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-triazole-4-carboxamide 
(3). White solid (m.p. 216.6 - 217.0 °C, from acetonitrile). Yield 97 %. 
1
H NMR (300 MHz, 
DMSO-d6): δ 4.07 (s, 3H), 7.43 (d, J = 7.8 Hz, 1H), 7.57, (t, J = 8.0 Hz, 1H), 8.00 (d, J = 8.1 
13 
Hz, 1H), 8.29 (s, 1H), 10.31 (s, 1H), 11.26 (br, 1H). 
13
C NMR (DMSO-d6): δ 42.1, 116.2 (q, 
J = 4.1 Hz), 119.8 (q, J = 3.8 Hz), 123.6 (q, J = 1.1 Hz), 124.2 (q, J = 272.3 Hz), 124.9, 129.4 
(q, J = 31.6 Hz), 129.8, 139.5, 158.8, 158.9. ESI-HRMS (m/z) [M - H]
-
 calcd. for 
C11H8F3N4O2 285.0605, obsd. 285.0594. 
4.1.8.3. 4-Hydroxy-1-methyl-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-carboxamide 
(4). White solid (m.p. 235.6 - 241.0 °C, from acetonitrile). Yield 96 %. 
1
H NMR (300 MHz, 
DMSO-d6): δ 4.19 (s, 3H), 7.47 (d, J = 7.7 Hz, 1H), 7.59 (t, J = 8.0 Hz, 1H), 7.83 (d, J = 8.2 
Hz, 1H), 8.20 (s, 1H), 9.90 (s, 1H), 12.98 (br s, 1H). 
13
C NMR (DMSO-d6): δ 38.6, 111.9, 
116.0 (q, J = 4.1 Hz), 120.3 (q, J = 3.9 Hz), 123.6 (q, J = 1.3 Hz), 124.0 (q, J = 272.4 Hz), 
129.6 (q, J = 31.7 Hz), 130.1, 138.8, 156.6, 158.1. ESI-HRMS (m/z) [M - H]
-
 calcd. for 
C11H8F3N4O2 285.0605, obsd. 285.0605. 
4.1.8.4. 2-(Cyclopropylmethyl)-5-hydroxy-N-(3-(trifluoromethyl)phenyl)-2H-1,2,3-triazole-4-
carboxamide (5). White solid (m.p. 187.3 - 188.4 °C, from acetonitrile). Yield 96 %. 
1
H 
NMR (300 MHz, DMSO-d6): δ 0.38 - 0.47 (m, 2H), 0.54‒0.64 (m, 2H), 1.25‒1.40 (m, 1H), 
4.18 (d, J = 7.2 Hz, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 8.01 (d, J = 8.2 
Hz, 1H), 8.27 (s, 1H), 10.20 (s, 1H), 11.30 (br, 1H). 
13
C NMR (DMSO-d6): δ 3.6, 10.7, 59.3, 
116.2 (q, J = 3.6 Hz), 119.8 (q, J = 3.7 Hz), 123.7 (q, J = 1.4 Hz), 124.1 (q, J = 272.3 Hz), 
124.8, 129.4 (q, J = 31.5 Hz), 129.8, 139.4, 158.6, 159.0. ESI-HRMS (m/z) [M - H]
-
 calcd. 
for C14H12F3N4O2 325.0910, obsd. 325.0907. 
4.1.8.5. 3-(Cyclopropylmethyl)-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-4-
carboxamide (6). White solid (m.p. 226.9 - 229.0 °C, from acetonitrile). Yield 79 %. 
1
H 
NMR (300 MHz, DMSO-d6): δ 0.35‒0.45 (m, 2H), 0.47‒0.57 (m, 2H), 1.30‒1.45 (m, 1H), 
4.47 (d, J = 7.3 Hz, 2H), 7.48 (d, J = 7.7 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.83 (d, J = 8.2 
Hz, 1H), 8.20 (s, 1H), 10.01 (s, 1H), 13.05 (br s, 1H). 
13
C NMR (DMSO-d6): δ 3.49, 11.2, 
55.3, 110.9, 115.9 (q, J = 4.0 Hz), 120.3 (q, J = 3.9 Hz), 123.5 (q, J = 1.1 Hz), 123.9 (q, J = 
272.4 Hz), 129.5 (q, J = 31.6 Hz), 130.0, 138.7, 156.5, 158.2. ESI-HRMS (m/z) [M - H]
-
 
calcd. for C14H12F3N4O2 325.0907, obsd. 325.0911. 
4.1.8.6. 1-Benzyl-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-carboxamide 
(7). White solid (m.p. 222.2 - 224.6 °C, from acetonitrile). Yield 97 %. 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.84 (s, 2H), 7.23‒7.39 (m, 5 H), 7.46 (d, J = 7.9 Hz, 1H), 7.57 (t, J = 8.0 Hz, 
1H), 7.82 (d, J = 8.1 Hz, 1H), 8.13 (s, 1H), 9.88 (s, 1H), 12.73 (br, 1H). 
13
C NMR (DMSO-
d6): δ 53.6, 111.3, 116.2 (q, J = 4.3 Hz), 120.5 (q, J = 4.3 Hz), 123.8 (q, J = 1.3 Hz), 124.1 (q, 
J = 272.4 Hz), 127.6, 128.1, 128.7, 129.6 (q, J = 31.7 Hz), 130.2, 135.8, 138.7, 156.5, 158.3. 
ESI-HRMS (m/z) [M - H]
-
 calcd. for C17H12F3N4O2 361.0907, obsd. 361.0908. 
4.1.8.7. 4-Hydroxy-1-(4-methoxybenzyl)-N-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazole-5-
carboxamide (8). White solid (m.p. 215.5 - 217.7 °C, from acetonitrile). Yield 98 %. 
1
H 
NMR (300 MHz, DMSO-d6): δ 3.71 (s, 3H), 5.75 (s, 2H), 6.90 (d, J = 8.6 Hz, 2H), 7.25 (d, J 
= 8.6 Hz, 2H), 7.47 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.83 (d, J =8.2 Hz, 1H), 8.14 
(s, 1H), 9.90 (s, 1H), 12.88 (br, 1H). 
13
C NMR (DMSO-d6): δ 53.2, 55.1, 111.1, 114.1, 116.1 
(q, J = 4.1 Hz), 120.5 (q, J = 3.9 Hz), 123.8 (q, J = 1.5 Hz), 124.1 (q, J = 272.1 Hz), 127.6, 
129.4, 129.6 (q, J = 30.4 Hz), 130.2, 138.7, 156.5, 158.4, 159.1. ESI-HRMS (m/z) [M - H]
-
 
calcd. for C18H14F3N4O3 391.1024, obsd. 391.1031. 
4.1.9. 4-Hydroxy-N-[3-(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide (2). The 
compound was obtained following the general procedure for synthesis of amides starting 
from 17.[28] Flash chromatography eluent: DCM / methanol 90/10 v/v. White solid (m.p. 
177.6 – 178.9 °C, from diisopropyl ether). Yield 40 %.1H-NMR (300 MHz, CD3OD):  7.46 
(1H, d, J = 7.9 Hz), 7.56 (1H, t, J = 8.0 Hz), 7.97 (1H, d, J = 8.2 Hz), 8.20 (1H, s). 
13
C-NMR 
14 
(75 MHz CD3OD)  118.3 (q, J = 4.0 Hz), 122.3 (q, J = 4.0 Hz), 125.1 (q, J = 1.3 Hz), 125.5 
(q, J =  272.5 Hz), 130.8, 132.2 (q, J =  32.3 Hz), 139.7, 140.8, 160.7, 166.0. MS (CI) 290 [M 
+ H]
+
. ESI-HRMS (m/z) [M - H]
-
 calcd. for C10H5F3N3O2S 288.0049, obsd. 288.0047. 
 
4.2. Expression and purification of recombinant human AKR1C3 and AKR1C2. 
Plasmid coding for human AKR1C3 was kindly provided by Prof. J. Adamski (Institute of 
Experimental Genetics, Genome Analysis Center, Neuherberg, Germany). The cDNA 
showed one mutation His5Gln in comparison to the NCBI sequence. This conservative 
mutation is described in the literature as a single nucleotide polymorphism (SNPs) and seems 
to be very common (refSNP: rs12529). Clone RC213538 containing human AKR1C2 cDNA 
was obtained by Origene. cDNA was sequenced by the C.R.I.B.I. – BMR Servizio 
Sequenziamento DNA, Padova (Italy). Then, it was amplified by PCR and, subsequently, 
subcloned using Xho I and Sal I into the same pGEX 2T- modified plasmid vector (kindly 
provided by Prof. J. Adamski), used for AKR1C3.  
Plasmids coding for AKR1C3 and AKR1C2 were transformed into Escherichia coli BL21 
(DE) Codon Plus RP (Agilent Technologies). For the protein expression, bacteria cells 
expressing AKR1C3 and AKR1C2 were grown in YT2X media supplemented with 
ampicillin at 37°C with continuous shaking. At OD600 nm = 0.6 the expression was induced 
by IPTG (0.5 mM). Bacteria were harvested 2 h after induction by centrifugation and stored 
at -20°C until use. For the AKR1C3 and AKR1C2 purification, bacteria were suspended in 
PBS supplemented with lysozyme (0.1 mg/ml) and protease inhibitor (Sigma). Then, bacteria 
were lysed by four freeze-thaw cycles followed by DNA-digestion with benzonase (25 U) in 
presence of MgCl2 5 mM. After centrifugation of the lysate for 30 min at 4°C and 13,000 x g, 
the supernatant was collected. Then, AKR1C3 and AKR1C2 were affinity purified via N-
terminal GST-tag on glutathione (GT) sepharose (GE-Healthcare) and cleaved of by 
thrombin according to the manufacturer’s protocol. Expression and purification was 
monitored by SDS-PAGE.   
 
4.3 In vitro AKR1C3 and AKR1C2 inhibition assays. 
The inhibition assays were carried out by using bacterial suspension or purified enzymes. In 
the screening of AKR1C3 inhibitors, bacteria expressing AKR1C3 were suspended in 100 
mM phosphate buffer pH 6.6 without lysis. The bacterial suspension (about 15 µg of 
proteins) was incubated with [
14
C]androstenedione (6 X 10
-4
 μCi) in the presence of Tween80 
(0.1 mg/mL), ATP (1 mM), MgCl2 (1 mM) and a NADPH generating system (1 mM NADP
+
, 
3 mM glucose-6-phosphate and 3 units of G-6-P dehydrogenase) for 30 min at 30°C with 
vigorous shaking. Inhibitors, when present, were added as solution in ETOH (10% v/v).  The 
enzymatic reaction was stopped by heating at 80 °C for 10 min. After extracting two times 
with ethyl ether (1.5 mL), the solvent was evaporated and the extract was separated on TLC 
silica gel plates using chloroform/ethyl acetate (4:1; v/v) as a developing system. Percent 
conversion of the labeled substrate to testosterone was estimated by integration from 
radioactivity scans with a System 200 Imaging Scanner (Hewlett-Packard, Palo Alto, CA, 
USA).  
In order to study the selectivity versus AKR1C2 of the active inhibitors of AKR1C3, the 
purified recombinant enzymes were used. The activity of the inhibitors was evaluated by 
using as a substrate S-tetralol in 96-well format. The reaction was fluorimetrically (exc/em; 
340 nm/ 460 nm) monitored by the measurement of NADPH production on a “Ensight” plate 
reader (Perkin Elmer) at 37°C. Assay mixture contained S-tetralol (in ETOH ), inhibitor (in 
ETOH), 100 mM phosphate buffer, pH 7, 200 µM NADP
+
, and purified recombinant enzyme 
(30 µl) in a final  volume of 200 µl and 10% ETOH. The S-tetralol concentration used in the  
AKR1C2 and AKR1C3 inhibition assay were 15 microM and 160 microM, respectively, the 
15 
some as the Km described  for the respective isoforms under the same experimental 
conditions. Percent inhibition with respect to the controls containing the same amount of 
solvent, without inhibitor, was calculated from the initial velocities, obtained by linear 
regression of the progress curve, at different concentrations of inhibitor. The IC50 values were 
obtained using PRISM 7.0, GraphPad Software. The values are the means of two separate 
experiments each carried out in triplicate. 
 
4.4 COX1 and COX2 inhibition assays  
References and selected compounds were tested for their ability to inhibit COX-1 and COX-2 
using a COX (ovine/human) Inhibitor Screening Assay Kit (Cayman Chemical Co., Ann 
Arbor, MI), following manufacturer’s instructions. The assay directly measured PGF2α by 
SnCl2 reduction of COX-derived PGH2 produced in the COX reaction. The prostanoid 
product was quantified via enzyme immunosorbent assay (ELISA); absorbance 
measurements were obtained on a PerkinElmer 2030 Multilabel Reader. IC50 values were 
obtained by linear regression using PRISM 7.0, GraphPad Software. Results were calculated 
as mean value ± standard error (SE) of at least three experiments. 
 
4.5 Tumor cell lines and cell culture. 
22RV1 castration-resistant prostate cancer cells were used. Cells were grown in RPMI 
supplemented with 10% (v/v) fetal calf serum, 2% (v/v) penicillin-streptomycin, 0.03% L-
glutamine and maintained at 37 °C in a humidified atmosphere containing 5% CO2. 
 
4.6 Cell proliferation assay. 
Cell growth inhibition was evaluated by sulforhodamine B colorimetric proliferation assay 
(SRB assay) modified by Vichai and Kirtikara.[36] 22RV1 cells were seeded into 96-well 
plates in RPMI containing 10% charcoal stripped serum, 2 % (v/v) penicillin-streptomycin 
and 0.03% L-glutamine, at a density of 10,000 cells/well and incubated at 37 °C with 5% 
CO2 for 24 hours to allow cellular adhesion. Various dilutions of inhibitors in ethanol were 
added in triplicate, and incubated for 72 h. Control cells were incubated with the same final 
concentration of ethanol (maximum concentration 1% v/v). The assay was done as previously 
described.[37] For co-treatment experiments, 22RV1 cells were treated with abiraterone (10 
µM) or enzalutamide (20 µM) with or without compound 8 (60 µM) for 72 h. The statistical 
analysis were performed with  PRISM 7.0, GraphPad Software. The values are the means of 
two separate experiments each carried out in triplicate. 
 
4.7 Inhibition of AKR1C3-Mediated Production of Testosterone in 22RV1 cells. 
22RV1 cells were seeded into 96-well plates in RPMI media containing 10% charcoal 
stripped serum, 2% (v/v) penicillin-streptomycin and 0.03% L-glutamine, at a density of 
30,000 cells per well, and were incubated at 37°C with 5% CO2 for 24 hours. Compound 8 
was added to the wells at 4 different concentrations and incubated for 1 hour. Equimolar 
(28nM) concentration of androstenedione was then added to the wells. The plate was returned 
to the incubator for a further 24h. Cell supernatant was removed for analysis of testosterone 
by ELISA following the manufacturer’s guide (Testosterone ELISA kit was purchased from 
Cayman Chemical Company). The ELISA plate was read at a wavelength of 405nM on a 
microplate reader. Analysis was performed using the Cayman Chemical Company’s online 
available analysis tool and data was quantitated against a standard curve generated in ELISA 
buffer. Cross reactivity to androstenedione was accounted for by adding these to cell-free 
wells of the ELISA plate. The statistical analysis were performed with PRISM 7.0, GraphPad 
Software. The values are the means of two separate experiments each carried out in triplicate. 
 
4.8 Western blot. 
16 
25 ug of total protein lysate was loaded for analysis by western blot. For detection of 
AKR1C3, 1:10,000 dilution of mouse monoclonal anti-AKR1C3 (Sigma Aldrich) was 
prepared in blocking buffer and added to the membrane with an overnight incubation at 4 °C 
on a shaker. Mouse B-actin (Sigma Aldrich) was used as internal control with a dilution of 
1:20,000 in blocking buffer, with overnight incubation at 4 °C on a shaker. Membranes were 
subsequently washed with PBST and incubated with secondary goat anti-mouse antibody 
(Thermo Fisher Scientific) at a dilution of 1:500 for 1 hour at room temperature on a shaker. 
Membranes were washed and exposed to UV light to detect target bands and captured using a 
digital camera. 
 
4.9 Molecular Modeling. 
The structures of compounds 6, 7 and 8, as well as the structures of the lead compound 
Flufenamic Acid, were built in their dissociated forms using the 2D Sketcher tool 
implemented in Maestro GUI. For each compound, an advanced conformational search was 
performed using OPLS_2005 as Force Field and setting 1000 maxium steps for each run. 
Quantum mechanics/molecular mechanics (QM/MM) docking was performed using 
Schrödinger QM-Polarized Ligand Docking protocol (QPLD).[35] For this purpose, the X-
ray crystallographic structure of AKR1C3 was retrieved from RCSB Database (PDB code: 
1S2C) and the generated conformers were docked. Before docking, the crystal structure of 
the protein underwent an optimization process using the Protein Preparation Wizard tool, 
implemented in Maestro
™
 GUI. Missing hydrogen atoms were added and bond orders were 
assigned. Then, DMS, non-structural water molecules and impurities (such as solvent 
molecules) were removed. The water 2152 was mantained in the binding site because its 
important water network,[26] also the cofactor NAP and the co-crystalized ligand Flufenamic 
Acid were maintained. Reorienting automatically optimized the hydrogen bond network: 
hydroxyl and thiol groups, amide groups of asparagine (Asn) and glutamine (Gln), and the 
imidazole ring in histidine (His). Moreover, the protonation states prediction of His—aspartic 
acid (Asp), glutamic acid (Glu), and tautomeric states of His—were accomplished using 
PROPKA.
™
 Finally, a restrained minimization of the protein structure was accomplished by 
converging heavy atoms to a 0.30 Å RMSD. A grid of 10 Å x 10 Å x 10 Å (x, y, and z) was 
created and centered on the co-crystalized ligand Flufenamic acid. The ligand was extracted 
from the structure and used for docking validation. The QPLD protocol was carried out using 
Glide Extra Precision (XP) mode, setting QM Level to Accurate (B3LYP functional, 6-
31G*/LACVP* basis set, ultrafine SCF accuracy level). In the QPLD procedure, after the 
first XP docking run, QM-derived charge is calculated for the top five poses of each 
compound in the field of the receptor. Then, a new XP docking is performed with new QM 
charges calculated. Finally, re-docking and re-scoring were performed, keeping the 10 
highest ranked poses.  
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